The #1 Source for Information on Lobular Breast Cancer
What is Lobular Breast Cancer?
Lobular breast cancer, also called invasive lobular carcinoma (ILC), is the 2nd most common type of breast cancer, accounting for about 15% of all breast cancer diagnoses with over 48,000 cases diagnosed each year. It’s time to advance research to better understand ILC and its differences, and refine treatment for patients.
Hear from LBCA Scientific Advisory Board and other ILC experts
Watch the most recent webinars and interviews with SAB members, researchers, patient advocates, and more.
The Latest News
October 15th Global Lobular Breast Cancer Awareness Day Events Around the World
LBCA’s cross-country Lobular Breast Cancer Awareness Tour concludes on October 15th in Massachusetts. Launched after the ILC Symposium in San Francisco on September 26th,
Research News
LBCA Awards the LBCA-Shannon Klingman Lobular Breast Cancer Clinical Research Grants
The Lobular Breast Cancer Alliance Inc. (LBCA), powered by Conquer Cancer’s EveryGrant®, has awarded a total of $1M through the LBCA-Shannon Klingman Lobular Breast Cancer Clinical
Education & Advocacy
ILC Training Series Expands with Four New On-Demand Lectures, Online Session Oct. 5th
LBCA is pleased to announce that four additional recorded lectures have been added to the Invasive Lobular Breast Cancer Training Series, hosted by Memorial Sloan
My ILC Story
My ILC Story: Meet Jane and Hear Her ILC Story
My name is Jane and I am 56 years old. Breast cancer has been part of my family history for as long as I can
My ILC Story: Meet Jane and Hear Her ILC Story
ILC Clinical Trials
Patients with invasive lobular carcinoma (ILC) can advance understanding of the disease by joining clinical trials. Few trials focus solely on ILC due to its lower incidence (10-15% of all breast cancers), but participation is crucial. Increased research could help improve detection, treatment, prevention of metastasis, and ultimately, develop a cure.